Combination of Bremachlorin PDT and Immune Checkpoint Inhibitor Anti-PD-1 Shows Response in Murine Immunological...

Area of Science:

• Oncology
• Immunotherapy
• Photodynamic Therapy

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a challenging cancer with poor response to immune checkpoint inhibitors (ICIs).
• Photodynamic therapy (PDT) can eliminate tumors and stimulate an immune response.

Purpose of the Study:

• To investigate Bremachlorin-mediated PDT's efficacy in reducing PDAC tumor burden.
• To assess PDT's ability to sensitize T-cell-high and T-cell-low PDAC tumors to PD-1 blocking ICIs.
• To evaluate survival and distant tumor response after PDT and ICI treatment.

Main Methods:

• Utilized Bremachlorin as a photosensitizer for PDT in murine PDAC models.
• Administered PDT alone and in combination with PD-1 blocking ICIs.
• Monitored tumor burden, survival rates, and immune responses in T-cell-high and T-cell-low tumors.

Main Results:

• Bremachlorin PDT demonstrated direct tumor killing and increased survival in both T-cell-high and T-cell-low PDAC.
• PDT sensitized T-cell-high tumors to PD-1 blockade, enhancing ICI efficacy.
• T-cell-high tumors showed a greater overall response to combination therapy compared to T-cell-low tumors.
• One mouse with T-cell-high tumors achieved complete regression of treated and distant tumors.

Conclusions:

• Combining Bremachlorin PDT with ICIs is a promising strategy for improving therapeutic responses in PDAC.
• PDT can overcome resistance to ICIs in PDAC by modulating the tumor immune microenvironment.
• This combination therapy offers a potential new avenue for treating difficult-to-treat pancreatic cancers.